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Thioredoxin reductase 1 (TrxR) is a homodimeric
selenoenzyme catalyzing thioredoxin (Trx) in an NADPH-
dependent manner. With regard to carcinogenesis, these
redox proteins have been implicated in cell proliferation,
transformation and anti-apoptosis. In the present study,
using a hamster cholangiocarcinoma (ChC) model, we
evaluated the immunohistochemical expression pattern of
TrxR in precancerous lesions and ChCs as well as in
normal bile ducts. The goal of this study was to determine
the potential role and importance of TrxR in cholangio-
carcinogenesis. For the ChC model, we obtained liver
tissue specimens with dysplastic bile ducts prior to the
development of ChC 8 weeks after initiation of the
experiment and ChC samples at 27 weeks. The immuno-
histochemical analysis showed diffuse cytoplasmic
overexpression of TrxR in the dysplastic bile duct
epithelial cells as well as in cholangiocarcinoma; this was
comparable to the negative or weakly positive in normal
and type 1 hyperplastic bile ducts. However, TrxR appeared
to be considerably down-regulated in the ChCs when
compared to the higher expression observed in the
dysplastic bile ducts. Therefore, these results suggest that
TrxR overexpression followed by down-regulation might
be an important event in cholangiocarcinogenesis, especially
at early stages including the cellular transformation of
candidate bile ducts. Further studies are however required
to determine whether TrxR may be a potential target
molecule for chemoprevention against cholangiocar-
cinogenesis. In addition, the molecular mechanism as well
as the importance of the loss of TrxR in the development
of cholangiocarcinoma, following dysplastic transformation
of bile duct cells, also remains to be clarified.
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Cholangiocarcinoma (ChC) is a highly malignant epithelial
cancer of the biliary tract. [22,23] In humans, primary sclerosing
cholangitis, hepatolithiasis, fibropolycystic diseases of the
biliary tract, Caroli’s disease and liver-fluke infection have
been considered as conditions that increase risk for the
development of ChC. [9,23] These risk conditions share, as
a common feature, long-standing inflammation as well as
chronic injury to the biliary tract, which may result in
producing harmful reactive oxygen species (ROS) inducing
DNA damage and chronically stimulating biliary cell
proliferation. [9,17,23] Therefore, it is possible that
dysfunction of the intracellular reduction-oxidation (redox)
regulatory system may be involved in cholangiocarcinogenesis.
Thioredoxin reductase-1 (TrxR) is a homodimeric
selenoenzyme belonging to the flavoprotein family of pyridine
nucleotide-disulphide oxidoreductases with mechanistic and
sequence identity, including a conserved -Cys-Val-Asn-Val-
Gly-Cys- redox catalytic site, to human glutathione reductases.
[16,20] TrxR catalyzes its physiological substrate, thioredoxin
(Trx), in an NADPH-dependent reaction. [16] The TrxR/Trx
couple constitutes a ubiquitous redox system in prokaryotic
and eukaryotic cells. [18] Trx has been implicated in a
variety of intra- and extracellular processes including
regulation of cell proliferation, apoptosis and regulation of
transcription factors such as nuclear factor-kappa B (NF-
κB), activator protein-1 (AP-1) and p53. [7,18-21] Therefore,
TrxR has been considered to play an important role in
regulating the cell growth and death and its dysregulation
has been closely linked to tumorigenesis. In fact, overexpression
of TrxR has been reported in a variety of human primary
cancers including: breast cancer, thyroid, prostate, non-small
cell lung carcinoma, malignant melanomas and mesothelioma
as well as in human cancer cell lines including Jurkat and
A549 cells. [2,4,8,13,25] Therefore, TrxR has been considered
a potential molecular target for anticancer drugs. [1,3,5,6,10,24]
The anti-cancer effects of doxorubicin and anti-tumor effects
of quinine, that are commercially available, are achieved by
inhibiting TrxR. [14,15] However, the role and importance
of TrxR in cholangiocarcinogenesis has not yet been studied.
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In the present study, we evaluated the immunohistochemical
expression pattern of TrxR in precancerous lesions represented
by dysplastic transformation of hyperplastic bile ducts and
biliary cancers, as well as in non-tumorigenic bile ducts,
type 1 hyperplastic and normal bile ducts, to determine the
potential role and importance of TrxR in cholangiocarcinogenesis
using a liver-fluke infected hamster ChC model.
Materials and Methods
Animals for cholangiocarcinoma model
Young Syrian golden hamsters, 130 to 150 g in body
weight, were purchased from Japan SLC (Japan). They were
housed five per polycarbonate cage in a clean rack to which
pre-filtered air was supplied and maintained at room
temperature (22~26
oC) under a 12 h light/dark illumination
cycle in an approved animal facility at Kangwon National
University in Korea. Animals were given a normal diet
(Samyang, Korea) and drinking tap water ad libitum
throughout the entire experimental period, except during the
(4 weeks) administration of the carcinogen in drinking
water. All of the hamsters were included in the experiment
after one-week acclimatization.
Experimental design for the cholangiocarcinoma model
The hamster ChC model was modified according to a
previous study. [12] Twenty-nine Syrian golden hamsters
were randomly divided into a control and a ChC model
group. On the first day of the experiment, the hamsters in the
experimental group were infected with 15 metacercariae of
liver fluke, Clonorchis sinensis. One day after the parasite
infection, they received 15 ppm of dimethylnitrosamine
(DMN; Kasei, Japan) in the drinking water for four weeks
with a normal diet. Thereafter, the hamsters were given
drinking tap water with a normal diet throughout the rest of
the study.
To obtain the precancerous liver tissues with dysplastic
bile ducts, we sacrificed five control and seven ChC model
hamsters at an interim stage of cholangiocarcinogenesis
(eight weeks after initiation of the experiment). Thereafter,
the remaining five control and 10 ChC model hamsters were
maintained for 19 weeks longer (total 27 weeks) to develop
cholangiocarcinoma. Necropsy of the hamsters was then
performed under ether anesthesia. We grossly examined the
liver of each sacrificed hamster and confirmed the liver-
fluke infection by identifying adult parasites in the biliary
tracts. The experimental design is depicted in Fig. 1.
Histology
Hamster liver tissues obtained at eight weeks and 27
weeks after the initiation of the experiment were fixed in
10% buffered neutral formalin for 48 h. After routine tissue
processing, the tissues were embedded in a low-melting-
point paraffin. Then 3 µm tissue sections were prepared for
hematoxylin and eosin (H&E) staining for histological
examination and for immunohistochemistry for the TrxR,
respectively.
Immunohistochemistry of TrxR
For immunostaining of TrxR, the avidin biotin complex
(ABC) method was used. After deparaffinization and
hydration, the liver tissue sections were immersed for 30
min in 100% methanol containing 0.3% hydrogen peroxide
(Showa, Japan) to block endogenous peroxidase activity.
After washing in distilled water and phosphate buffered
saline (PBS, pH 7.2), the sections were microwaved in
preheated DAKO antigen retrieval solution (pH 6.0) for 15
min at high power, followed by 30 min detergent treatment
at room temperature with 0.05% tween 20 in PBS (pH 7.2).
After washing in PBS, the tissue sections were incubated in
normal blocking serum provided in the Vectastatin Elite
avidin-biotin peroxidase complex immunostaining kits.
Avidin D and biotin blocking reagents supplied in the Vector
Avidin/Biotin blocking kit were applied to the tissue
sections according to the manufacturer’s instruction to
minimize background staining due to endogenous biotin or
biotin-binding proteins, lectins, or nonspecific binding
substances present within the tissue sections. The sections
Fig. 1. Experimental protocol. For the hamster cholangiocarcinoma model, 15 metacercariae of  Clonorchis sinensis were used for
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were then incubated overnight at 4
oC with a primary
antibody for TrxR (1 : 500; Upstate Biologicals, USA). For
the negative controls, PBS was applied to the sections
instead of a primary antibody. The tissue sections were then
incubated for 40 min at room temperature with a biotinylated
secondary antibody, followed by a 30 min incubation with
Vectastatin Elite ABC reagent (Vector, USA) at room
temperature. The specific bindings of antibodies within the
tissue sections were visualized with 3,3-diaminobenzidine
tetrahydrochloride (Dako, Denmark) solution diluted in
PBS, and the sections were then counterstained with Mayer
hematoxylin. A selected tissue slide, demonstrating a typical
positive reaction, was used as a positive control for every
batch of TrxR immunostaining.
Results
Gross findings and histopathology in the hamster ChC
model
Two hamsters died at three weeks after initiation of the
experiment during DMN treatment. The livers of the hamsters
sacrificed during the interim stage of cholangiocarcinoma
(eight weeks after initiation of the experiment) were grossly
enlarged and yellowish brown in color with multiple small
nodules (1~5 mm) on the surface. The common bile ducts
and hepatic bile ducts were severely dilated with the adult
liver flukes. Histologically, intrahepatic hyperplastic and
dysplastic bile ducts of various sizes and shapes were
commonly evident in the periportal areas with prominent
fibrosis. The hyperplastic bile ducts had a normal structure
lined by simple cuboidal bile duct epithelial cells (Fig. 2B),
while dysplastic bile ducts were determined based on their
atypical duct structures characterized by irregular lumina,
multi-layers of epithelial cells, sometimes showing papillary
projection, and transformed individual cellular morphology
exemplified by taller and larger epithelial cells with larger
and heterochromatic nuclei (Fig. 2C). Mitotic figures were
quite often evident in the dysplastic bile ducts. Desmoplastic
connective tissue with inflammatory cell infiltration surrounded
the proliferating hyperplastic and dysplastic bile ducts.
Large intrahepatic and hepatic ducts, severely dilated by the
presence of adult parasites, showed epithelial cell proliferation
with surrounding desmoplastic reaction of connective tissue
in which eosinophils, lymphocytes and plasma cells had
massively infiltrated. These histopathological findings were
consistently noted in all hamster livers sacrificed at the
interim stage of cholangiocarcinogenesis. Only one case out
of the seven hamsters sacrificed at the interim stage of
cholangiocarcinogenesis developed cholangiocarcinoma.
All the hamsters survived up to 27 weeks after initiation of
the experiment had developed cholangiocarcinoma in the
livers. Histologically, the cholangiocarcinomas that developed
were tubular or tubulopapillary cystic types composed of
various shapes of tubules or cyst-like structures lined by
single to multi-layered tall columnar to cuboidal neoplastic
cells and intermittent mucus-producing goblet cells (Fig.
3A-C). The tubules and cysts in general contained relatively
large amounts of mucus in their lumina. The tumor cells
were aggressively invading adjacent liver parenchyma forming
irregular tubular structures or solid sheets of undifferentiated
neoplastic cells accompanied by surrounding desmoplastic
reaction of connective tissue (Fig. 3A-C). The neoplastic
cells had large round nuclei, resulting in a high nucleus/
cytoplasm ratio. The supporting connective tissue consisted
of bundles of abundant collagen fibers containing interspersed
inflammatory cells (Fig. 3A-C).
Immunohistochemistry of TrxR
In the liver tissues at the interim stage of the ChC model,
diffuse cytoplasmic overexpression of TrxR was noted in
the dysplastic bile duct epithelial cells (Fig. 2c), but the
TrxR observed was in general negative or weakly positive in
the hyperplastic bile ducts (Fig. 2b). However, at times the
immunoreactivity of TrxR in the hyperplastic bile duct
Fig. 2. Microphotographs of the liver. A and a, normal bile duct;
B and b, type 1 hyperplastic bile ducts; C and c, dysplastic bile
ducts. Dysplastic bile ducts and large hyperplastic bile ducts
showed strong immunoreactivity for TrxR, while normal (arro w
in a) and type 1 hyperplastic bile duct cells (arrow in b) were
negative or weakly positive. Dysplastic bile ducts were
composed of transformed multi-layered bile duct cells forming
irregular lumina. A, B, C; H&E stain, a, b, c; immuno-
histochemistry for the TrxR. bars = 25 µm. 214 Byung-IL Yoon et al.
epithelial cells was heterogenous and could be negative to
strong positive in the same bile duct. In some dysplastic bile
ducts, a stronger positive staining was noted at the base of
the bile duct cells. The hyperplastic large hepatic bile ducts,
containing adult parasites, showed the strongest
immunoreactivity for TrxR. The normal bile ducts from the
control hamsters were almost negative or very weakly
positive for immunoreactivity of TrxR (Fig. 2a).
For all of the tubular types of ChCs that developed, TrxR
was diffusely expressed in the cytoplasm of the neoplastic
cells (Fig. 3a-c). Compared with the expression level in the
dysplastic bile duct cells, TrxR immunoreactivity seemed to
be less pronounced in the biliary cancer cells; however, it
was still much higher than that observed in normal and type
1 hyperplastic bile ducts. The undifferentiated neoplastic
cells forming solid sheets and invading the liver parenchyma
totally lost TrxR immunoreactivity in their cytoplasm (Fig.
3c). Type 1 hyperplastic bile ducts showed negative or
weakly positive for TrxR, but they were at times strongly
positive. Sinusoidal cells showed a strong immunoreactivity
for TrxR, while hepatocytes were negative using our
immunostaining protocol.
Immunoreactivity of the liver cell components for TrxR is
summarized in Table 1. 
Discussion
The critical properties of neoplastic cells include maintaining
their ability to proliferate, evading autonomous cell death
programs and host-derived immune attacks, and protecting
themselves against the harmful subcellular by-products
including free radicals and ROS which are excessively
generated during hyperactive cellular proliferation. One of
the strategies that neoplastic cells use to survive is to utilize
the intracellular redox system such as the TrxR/Trx couple,
glutathione (GSH)/oxidized glutathione (GSSG) couple and
other related enzymes. Trx has been shown to have a variety
of intra- and extracellular functions. [18-21] In addition to
an antioxidant function, Trx has been implicated in cell
proliferation and survival by increasing DNA synthesis in
synergy with a number of cytokines and by regulating
various transcription factors. [7,18-21] TrxR catalyzes
oxidized Trx into reduced Trx in a NADPH-dependent
manner, enabling active functioning of Trx. [18-21] Since
TrxR has been shown to be highly expressed in some tumors
including gastric cancer, [2,4,8,13,25] TrxR has attracted
attention for further understanding of its role in carcinogenesis
of a variety of cancers as a potential target molecule for
treatment. [1,3,5,6,10,24] In the present study, we investigated
the expression pattern of TrxR in ChCs and precancerous
dysplastic bile ducts in a hamster ChC model.
According to previous studies using a hamster ChC
model, ChC usually develops at 16 weeks after initiation of
the experiment. [12] Therefore, we considered that at eight
weeks an early stage ChC would be present. In the hamster
livers sacrificed at eight weeks, proliferating dysplastic bile
Table 1. Immunoreactivity of TrxR in liver cell populations
during hamster cholangiocarcinogenesis
Cell population 8 weeks 27 weeks
Normal bile ducts (5)* − ~ ±  − ~ ± 
Type 1 hyperplastic bile ducts (7)  − ~ ± 
(+++)**
 − ~ ± 
(+++)**
Dysplastic bile ducts (7) ++ ~ +++  + ~ +++
Large hyperplastic hepatic ducts (17)  +++   +++
Cholangiocarcinoma (10)  ND + ~ ++
Hepatocytes (27) −  − ~ ± 
Sinusoidal cells (27)  +++   +++
*( ), number of the hamsters examined.
**, Individual strong positive cells were often noted. 
ND, not determined.
Fig. 3. Microphotographs of cholangiocarcinomas that developed
in the hamster model. A and a, tubular type; B and b, tubulocystic
type; C and c, undifferentiated type. Immunoreactivity o f
cholangiocarcinomas for TrxR was down-regulated compared to
dysplastic bile ducts (c in Fig. 2); however, it was still muc h
higher than in the normal and type 1 hyperplastic bile duct cells.
Expression of TrxR was independent of the classified ChC types
except for the undifferentiated type. The neoplastic cells of the
undifferentiated type (arrow in C) totally lost TrxR immuno-
reactivity (arrows in c). A, B, C; H&E stain, bars = 50  µm; a, b,
c; immunohistochemistry for TrxR, bars = 25 µm.Overexpression of TrxR in dysplastic bile ducts and cholangiocarcinomas 215
duct cells were characterized by multi-layered tall cuboidal
epithelia forming irregular lumina, frequently with interspersed
mucus-secreting cells. The dysplastic bile duct epithelial
cells showed strong cytoplasmic expression of TrxR, which
was comparable to the negative or weakly positive immuno-
reactivity of normal and type 1 hyperplastic bile ducts. This
unique expression of TrxR in the dysplastic bile ducts may
suggest a role of TrxR in the early stages of celluar
transformation prior to ChC development. Improved activation
of TrxR may increase the opportunity for the transformed
bile duct cells to survive cellular apoptosis signaling and
continue to proliferate in the microenvironment of the
injured biliary cell, which is an inevitable event that
progresses to cholangiocarcinogenesis.
Highly expressed TrxR was also evident in the cholangio-
carcinomas that developed in the hamster livers sacrificed at
27 weeks in this study. However, the expression level was
considerably down-regulated compared with the highly
expressed dysplastic bile ducts at the interim stage of
cholangiocarcinogenesis. These findings suggest that once a
tumor has become established and/or as the tumor advances,
highly expressed TrxR appears to diminish. It could not be
determined in this study what significant effect such down-
regulation of TrxR immunoreactivity could have in association
with carcinogenesis; however, it might be associated with
the alleviation of inflammation followed by fibrosis surrounding
the neoplastic bile ducts.
The expression pattern of TrxR may be one of the
characteristics of specific cancers. Depending on the tumor
involved, a large difference in TrxR mRNA and protein
expression levels has been reported. [11] Loss of TrxR had
been demonstrated in colon cancers and the transplanted
HT-29 colon cancer cell line, while fibrosarcoma and gastric
cancers usually show high expression levels. [11] The TrxR
expression level has also been shown to be associated with
tumor cell differentiation in specific tumors, as Soini et al.
[25] reported a lower expression level of TrxR in high grade
non-small cell lung carcinomas. This concept could also be
applied to the cholangiocarcinoma, since undifferentiated
neoplastic cells forming solid sheets and invading into
adjacent liver parenchyma totally lost TrxR immunoreactivity,
compared with the mild to moderate overexpression of TrxR
in the well-differentiated neoplastic cells. Further study
using human cholangiocarcinomas should verify a possible
association between TrxR immunoreactivity and tumor cell
differentiation grade.
In summary, TrxR was overexpressed in dysplastic bile
ducts and cholangiocarcinoma, suggesting a significant role
of TrxR in cholangiocarcinogenesis, especially in the early
stages including the transformation of candidate bile duct
cells. However, down-regulation of TrxR in the biliary
cancer cells requires further study to determine whether
TrxR may be a potential target molecule for chemoprevention
against cholangiocarcinogenesis. In addition, the molecular
mechanism and importance of loss of TrxR in the process of
the development of cholangiocarcinoma, following dysplastic
transformation of bile duct cells, also remains to be clarified.
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